Skip to main content
Premium Trial:

Request an Annual Quote

Neogen, Gencove Form Animal Genomics Alliance

NEW YORK — Food and animal safety firm Neogen said today that it has partnered with Gencove on the development of new animal genomics tests.

Neogen said that the deal will enable it to include Gencove’s low-pass whole-genome sequencing technology with its GeneSeek Genomic Profiler genotyping arrays. Additional terms were not disclosed.

"Partnering with Neogen, the largest genomic solutions service provider in agriculture worldwide, will give both our organizations the opportunity to advance the agricultural genomics industry by leading in the implementation of new technologies," Joe Pickrell, cofounder and CEO of New York City-based Gencove, said in a statement.

Early last year, Neogen acquired Canadian animal genomics firm Delta Genomics Centre. Other recent acquisitions for the Lansing, Michigan-based company include the assets of The University of Queensland Animal Genetics Laboratory, Brazilian animal genomics lab Deoxi Biotecnologia, and California-based animal genomics business Scidera Genomics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.